

**CURRICULUM VITAE (CV)**

Georgios Pentheroudakis

**Professor of Oncology,  
School of Medicine, University of Ioannina**

**Head of Dept of Medical Oncology,  
Ioannina University Hospital**

**Chair, ESMO Guidelines Committee**

<b>Publications</b>	
PubMed	256
<b>H Index</b>	
Scopus	39

Department of Medical Oncology  
Medical School, University of Ioannina, Greece  
45500 Ioannina

*March 2019*

## CV

**NAME & SURNAME:** George Pentheroudakis  
**DATE OF BIRTH:** 3 December 1967  
**PLACE OF BIRTH:** Thessaloniki  
**MARITAL STATUS:** Married  
**MEDICAL EDUCATION:** Faculty of Medicine, University of Thessaloniki, 1991

### POSTGRADUATE MEDICAL EDUCATION AND CAREER

**1992-93:** Compulsory rural practice at the Health Center of Voulgareli, Arta  
**1993-94:** Medical Resident in the Department of Internal Medicine, Veria General Hospital.  
**1994-96:** Medical Resident in the 3rd Department of Chemotherapy, Theagenion Anticancer Hospital, Thessaloniki.  
**1996-99:** Medical Resident in the 4th University Department of Internal Medicine, Ippokrateio Hospital, Thessaloniki.  
**1999:** Acquisition of the Certificate of Completion of Specialty Training in Internal Medicine on 23-2-1999 in Thessaloniki.

**1999-2000:** Senior House Officer III in Medical Oncology at the Department of Oncology, Glasgow Royal Infirmary, Glasgow, Great Britain. Salaried post.

**2000-2002:** Specialist Registrar in Medical Oncology, National Training Number WOS/AD/005/N) at the Beatson Oncology Centre, Glasgow, Great Britain. Salaried post.

**2002:** Acquisition of the Certificate of Completion of Specialty Training in Medical Oncology on 17/6/2002, Athens.

**2003:** Appointed as Specialist in Medical Oncology in the Department of Medical Oncology, Ioannina University Hospital on 5/9/03.

**2006:** Successful presentation of PhD thesis in the Faculty of Medicine of the University of Ioannina with the topic «Study of the mechanisms of CA 15-3, CA 19-9 mucinous glycoprotein marker rise in the serum of operated early breast cancer patients on adjuvant chemotherapy and G-CSF compared to control groups».  
 (Doctor of the Faculty of Medicine - Ioannina University (4/4/06).

Election as Lecturer in the Faculty of Medicine - Ioannina University, in December 2006.

**2010:** Appointed as Assistant Professor of Oncology in the School of Medicine - Ioannina University

**2011:** Coordinator of the European Society of Medical Oncology (ESMO) Faculty in Neuroendocrine, Endocrine Tumors and Cancer of Unknown Primary.

Coordinator of the Gastrointestinal Cancer Working Group of the Hellenic Cooperative Oncology Group (HeCOG) and of the Cancer of Unknown Primary (CUP) Working Group of the Hellenic Cooperative Oncology Group (HeCOG).

**2012:** Co-Chair of the ESMO Guidelines Working Group.

Chairman of the Scientific Committee of the Hellenic Cooperative Oncology Group (HeCOG), until 2016.

Member of the Board of Directors of the Hellenic Foundation of Cancer Research (HeFCR), until present time.

**2014:** Appointed as Associate Professor of Oncology in the School of Medicine- Ioannina University (10/10/2014)

**2016:** Elected as Chair of the ESMO Guidelines Committee and member of the ESMO Executive Board of Directors.

Head of Department, Dept of Medical Oncology, University of Ioannina, Greece (since 1/9/2016).

**2017:** Member of the European School of Oncology (ESO) Core Faculty in GI cancer (<http://www.eso.net/pagine-interne/eso-core-faculty.html>)

Member of the National Committee of Pharmacovigilance, National Drug Agency (EOF).

Member of the Task Force for development of Therapeutic Protocols in Gastrointestinal Cancer, EOppy, Hellenic Ministry of Health.

Evaluator of oncology clinical trials for the National Ethics Committee (EED).

## **MEMBER OF SCIENTIFIC SOCIETIES/ JOURNALS**

### SCIENTIFIC SOCIETIES

1. European Society of Medical Oncology
2. American Society of Clinical Oncology
3. Hellenic Society of Medical Oncology
4. Ioannina Medical Association
5. Hellenic Cooperative Oncology Group (HeCOG)

### Participation in Editorial Boards of Medical Journals

1. Forum of Clinical Oncology, Hellenic Society of Medical Oncology
2. Cancers, MDPI AG, Basel, Switzerland
3. Mediterranean Oncology Journal
4. Cancer Treatment Communications, Elsevier
5. Journal of Cancer Research, Hindawi Publishing
6. *EJSO - European Journal of Surgical Oncology*
7. BioMed Research International, Hindawi Publishing Group.
8. Journal of Medical Genomics and Biomarkers, Herald Scholarly Open Access, NY 13903, USA
9. Rare Cancers and Therapy
10. Oncology and Therapy, Springer
11. ESMO Open-Cancer Horizons

### Reviewer for the following esteemed high Impact Factor journals:

Annals of Oncology, European Journal of Cancer, Lancet , Lancet Oncology, Nature, Nature Reviews Clinical Oncology, Clinical Cancer Research, British Journal of Cancer, Cancer, Cancer Research.

## **FOREIGN LANGUAGES**

1979: French (Certificat Superieure de langue francaise Sorbonne).

1986: English (Cambridge Proficiency Certificate of English Language).

1998: Italian ( Diploma di lingua Italiana, Istituto Culturale Salonicco).

## **DOCTORAL DISSERTATIONS-POSTGRADUATE PROGRAMS**

### Supervisor at doctoral dissertations-PhDs:

1. Circulating tumor cells and epithelial-mesenchymal transition phenotype in Cancer of Unknown Primary (CUP) patients.  
PhD thesis, Dr S Boussios, 2011-2015. Medical School, University of Ioannina.  
Successfully defended on 3/11/2016.
2. Prognostic importance of clinicopathologic factors and immunohistochemical profiling of Cancer of Unknown Primary (CUP).  
PhD thesis, Dr D Petrakis, 2010-2014. Medical School, University of Ioannina.  
Successfully defended on 5/2/2015.
3. A study of the biology of Androgen Receptor, downstream effectors and its activation markers in breast cancer.  
PhD thesis, Dr G Fotopoulos, 2012-2016. Medical School, University of Ioannina.  
Successfully defended on 22/12/2017.
4. Incidence, clonal evolution over time and correlation with tissue of RAS mutations in cell free plasma DNA and in platelet-resorbed tumour RNA in patients with advanced colorectal cancer on anti-EGFR moAbs.  
PhD thesis, Dr G Zarkavelis, 2015-2019. Medical School, University of Ioannina.
5. A study of the incidence, clinicopathological associations, impact on neurocognitive function, IQ and quality of life of Chemotherapy Brain in women with early breast cancer managed with adjuvant chemotherapy.  
PhD thesis, MSc F Masoura, 2015-2018. Medical School, University of Ioannina.
6. An immunohistochemical study of the host immunological response in resected brain metastases and matched primary solid tumours.  
PhD thesis, Alexandra Papadaki, March 2017-2021, Medical School, University of Ioannina.

### Member of the 3-member Supervisor Committee:

7. Study of genotypic and phenotypic characteristics in primary and metastatic CRC.  
PhD Thesis, Kyriakos Xatzopoulos, Medical School, University of Thessaloniki, 2014-2018.

8. Molecular characteristics of outcome in resected stage III colorectal cancer patients.  
PhD Thesis, Ioannis Kyrochristos, Medical School, University of Ioannina, 2016-2020.
9. A flow cytometric, molecular and epidemiological study of acute leukemias: diagnosis, management and prognosis.  
PhD Thesis, Ioanna Tsoulfi, Medical School, University of Ioannina, 2018-2021.
10. A prospective registry study of patients with acute coronary syndrome and a history of malignancy.  
PhD Thesis, Constantine Siaravas Medical School, University of Ioannina, 2018-2021.
11. A study of KRAS NRAS mutations by means of digital BEAMING PCR in cell free tumour DNA in patients with metastatic colorectal cancer and their impact on therapeutic strategies.  
PhD Thesis, Myrto Kastrisiou, Medical School, University of Ioannina, 2018-2021.
12. A study for the non-inferiority of observation with radiotherapy versus axillary nodal dissection in women with up to 3 positive sentinel lymph nodes from T1-2 mammary adenocarcinoma.  
PhD Thesis, Dimitra Peristeri, Medical School, University of Ioannina, 2018-2022.

### **EDUCATIONAL-TEACHING ACTIVITY**

Active participation in the educational and teaching activity of the Department of Medical Oncology, Ioannina University Hospital - Training of medical residents of Medical Oncology and Internal Medicine since 2003.

Daily guidance and training of medical students during their visits in the Oncology Department and the Outpatient Clinics within the framework of the courses "Nosology" and "Pathophysiology". Participation in the teaching of the pregraduate courses of the Medical School, University of Ioannina: "Nosology", "Pathophysiology I", "Pathophysiology II", "Internal Medicine" and in the Elective Course "Medical Oncology" to medical students from 2010 until now.

Head of the column «Educational Pages» of the Forum of Clinical Oncology, official journal of Hellenic Society of Medical Oncology, 2006-2010.

Participation in the development of Consensus Recommendations of the Hellenic Society of Medical Oncology (HeSMO) for Colorectal Cancer (2011, member, 2017, Coordinator) and for Esophagogastric Cancer (2011, Coordinator, 2016 Coordinator).

Composer of European Society of Medical Oncology E-Learning Modules ([www.esmo.org](http://www.esmo.org)):

- a. Cancer and Pregnancy E-Learning Module, 2013
- b. Cancer in the Adolescents and Young adults E-Learning Module, 2014
- c. ESMO E-Learning: Optimising Outcomes for Patients with Advanced Colorectal Cancer, 2016

Authorship of chapters in 13 medical books, of national and of international circulation (Appendix B) .

Organisation of Greek and international oncology conferences.

Chair of scientific and educational sessions in several national and international oncology congresses over the last 15 years.

Participation as tutor in the courses of the Hellenic Oncology Academy (EAKO) of the Hellenic Society of Medical Oncology (EOΠE) for Medical Oncology trainees, Athens, 2009-2017

## **RESEARCH ACTIVITY AND INTERESTS**

Specific research interests:

Cancer of Unknown Primary,  
 Cancer and Pregnancy,  
 Gastrointestinal Oncology,  
 Translation Research in Oncology,  
 Clinical Pharmacokinetics,  
 Development of new Anti-neoplastic Therapies at Phase I/II studies,  
 Molecular Oncology,  
 Immuno-Oncology,  
 Liquid Biopsies.

A full description of research initiatives in oncology is not entertained in this CV and is more objectively reflected in the Publication list (Appendix A).

Sub-investigator in the following clinical trials:

### **Beatson Oncology Centre**

1. A phase I dose-escalation study of ZD0473 combined with paclitaxel in refractory solid malignancies.
2. A dose-finding phase I study of BBR3464 in patients with advanced solid tumours.
3. A dose-finding phase I study of epirubicin, cisplatin and escalating doses of capecitabine in patients with advanced gastroesophageal carcinoma.
4. A dose escalating phase I study of Applidine in patients with refractory malignancies.
5. A phase II study of docetaxel combined with trastuzumab in patients with metastatic breast cancer overexpressing HER2.
6. A phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-Ring-modified camptothecin analogue in adults with solid tumors.

### **Industry-sponsored clinical trials, Medical School, University of Ioannina.**

CRAD001LGR04	An observational study of the safety and efficacy of Afinitor® in patients with metastatic renal cancer progressive after anti-vegf therapy
--------------	---

I4T-MC-JVBB(b)	A randomised double-blind phase III trial of FOLFIRI with ramucirumab or placebo in patient with mCRC after oxaliplatin and bevacizumab-based first line therapy.
M022998	A phase III study of the safety and efficacy of continued and re-introduced bevacizumab in combination with chemotherapy for patients with advanced breast cancer progressive after 1 <sup>st</sup> line chemotherapy with bevacizumab
12444	A phase iii randomized, double-blind, placebo-controlled trial comparing capecitabine plus sorafenib versus capecitabine plus placebo in the treatment of locally advanced or metastatic her-2 negative breast cancer
CSTI571BGR07	A prospective, multicenter, national, phase iv observational study to assess recurrence free survival and safety of imatinib in treatment of patients with gastro-intestinal stromal tumour in adjuvant setting in greece
SUTENT A6181099	A randomised phase III study of sunitib in combination with capecitabine versus capecitabine for patients with breast cancer previously exposed to chemotherapy
SCH619734	A phase II multicentre double-blind placebo-controlled trial of the safety and efficacy of SCH619734 for the management of nausea and vomiting induced by chemotherapy
VX001	A multicentric randomised double-blind placebo-controlled phase Iib trial of VX001, a peptide anticancer vaccine, for the control of lung cancer after completion of first line therapy, in patients with HLA0201 TERT-positive stage IV NSCLC
TDM1	A multicentre study of TDM1 in patient with advanced HER2+ breast cancer priorly treated with trastuzumab and chemotherapy
AMG337	A multicentre phase II trial of safety and PK of AMG337 in patients with advanced gastric cancer with MET amplification
MOSAIC	A randomised study of infusional 5FU/leucovorin with or without Oxaliplatin for the adjuvant treatment of patients with resected stage B2-C colon carcinoma (Sponsor Sanofi-Aventis, 2002-2004).
20130111	A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG 337 in Subjects with MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors, 2013-2015.



**Most recent clinical trial experience**

<b>Study Name or Code</b>	<b>Participation Period</b> (total in years)	<b>Role in the study</b> (Principal Investigator or Sub-Investigator or Study Coordinator or Other, specify)	<b>Therapeutic Area:</b>	<b>Clinical Phase</b> (Phase I, II, III, IV)	<b>Study Status</b> (In Progress or Closed)
Modul MO29112	Sep 2015- ongoing	PI in industry-sponsored trial	CRC	III	In Progress
20120286	Oct 2015- ongoing	PI in industry-sponsored trial	CRC	Observational	In Progress
DC419AC0000 3	Jan 2016- ongoing	PI in industry-sponsored trial	Lung	III	In Progress
SECURE	FEB 2016- ongoing	PI in industry-sponsored trial	CRC	Observational	In progress
20130232	Mar 2016- ongoing	PI in industry-sponsored trial	SCCHN	I	In Progress
20110265	Jun 2016- ongoing	PI in industry-sponsored trial	Melanoma	III	In Progress
PREMISE 9785- MA1002	JUL 2016- ongoing	PI in industry-sponsored trial	Prostate	Observational	In progress
CINC280A2105	NOV 2016- OCT 2017	PI in industry-sponsored trial	Solid tumors	I	Closed
CA209-649	FEB 2017- ongoing	PI in industry-sponsored trial	Gastric	III	In progress
A-96-52030- 737 G-NET	JUL 2017	PI in industry-sponsored trial	G-NET	Observational	In progress
HE37/12	APR 2013- ongoing	Principal Investigator in HECOG trial	Cholangio	II	In progress

HE9A/14 (CABA-BONE)	SEP 2015- ongoing	Principal Investigator	in	Prostate	II	In progress
HE7/12 (AGAPP)	NOV 2012- ongoing	Coordinating Investigator	in	Gastric	II	In progress
HE6A/13 (AMALTHEA)	MAY 2014-OCT 2017	Coordinating Investigator	in	Colon	II	Closed
HE6B/16 (AREPEAT)	OCT 2017- ongoing	Coordinating Investigator	in	Colon	II	In progress
CA209-901	OCT 2017- ongoing	PI in industry-sponsored trial		Urothelial	III	In progress
- RACING: Phase Ib/II study of Nab Paclitaxel/Ge mcitabine and Ramucirumab in advanced pancreatic cancer		Coordinating Investigator	in	Pancreatic cancer	Ib	In progress

Active participation in the development and conduct of phase I-III clinical trial protocols of clinical and translational research under the umbrella of the Hellenic Cooperative Oncology Group (2003-2017) as Coordinating Investigator.

Close cooperation with leading scientists, pharmacologists, pathologists, molecular biologists on the verge of laboratory and translation research within the framework of the Faculty of Medicine - Ioannina University- and the Hellenic Cooperative Oncology Group (HeCOG), during the years 2003-2017.

Coordinator of the Clinical Trials Unit of the Dept of Medical Oncology, Ioannina University Hospital.

My active areas of interest which I am currently pursuing with ongoing research projects and collaborations are the following:

- Study of pivotal biomolecules of tumour angiogenesis and biomarkers of benefit from anti-angiogenic therapies in breast and GI carcinomas.
- Profiling activity markers of the EGFR pathway and discovery of biomarkers predictive of benefit from anti-EGFR targeted therapeutics in colon cancer.
- Study of the molecular biology of Cancer of Unknown Primary and identification of a prometastatic CUP-specific signature as well as targetable biomolecules.
- Study of the host immune system, its effector and regulator molecules, for its significance in effecting antitumour functions on its own, or in combination with therapeutic monoclonal antibodies (anti HER2, anti EGFR) as well as for its prognostic significance in breast and GI tumours.

- Study of the host antineoplastic immune response in Cancer of Unknown Primary and in cerebral metastatic lesions from solid tumours.
- Design and launch of Investigator-Initiated clinical trials of novel, targeted therapeutics for the management of patients with breast, GI tumours and CUP (phase I-III in the context of HeCOG).
- Study of cancer gene mutations in cell-free DNA from plasma and matched cancer tissue of patients with advanced malignancies (in the context of the CARING network of cooperating University of Ioannina research laboratories) for the design of rational personalized therapeutic strategies.

Participation, as investigator or co-investigator, in research protocols of translational research on cancer biology, new drug development and cancer biomarkers, submitted to and financed by grants of the Ioannina University, Hellenic Society of Medical Oncology, Greek National grants, 2004-2017. Presentations of clinical and translational research projects in national and international medical conferences, publications in medical journals and books are attached (**Appendices**).

Session Chair at scientific sessions in several Hellenic conferences as well as in ESMO Congresses 2009-2019.

**Research output and Scientific Impact Metrics (March 2019):****Publications in peer-reviewed Index Medicus journals of English language:**

PubMed 256

**Publications in Greek, peer-reviewed, medical-type journals: 9**

**Chapters in medical editions/books: 14**

**Citations, March 2019:**

Scopus 5319

Without self citations 4903

**H INDEX 39****Presentations in medical conferences**

International 82

Greek 58

## **ORGANIZATIONAL AND MANAGEMENT EXPERIENCE**

Participation in management and financial organization of clinical and translational research protocols in the Department of Medical Oncology – Medical School, University of Ioannina. Duties involved administration, funding, staff employment, organizational and financial management of clinical/translational research infrastructures and responsibility for their viability.

Member of the Board of Directors of the Clinical Trials and Applied Research Group in Oncology of the University of Ioannina (CARING, 2011-2018).

Member of the Scientific Committee of the Hellenic Cooperative Oncology Group (HeCOG) since 2005, Chairman of the HeCOG Scientific Committee (2012-2016).

Member of the Organizing Committees of >40 medical conferences.

Faculty member (since 2007) and later Coordinator (since 2011) of the ESMO Working Groups for

- the Cancer of Unknown Primary (CUP) and Neuroendocrine Tumors
- the Adolescent and Young Adult Oncology

Member (since 2007), Co-chair (since 2012) and Chair (since 2016) of the European Society of Medical Oncology (ESMO) Clinical Practice Guidelines Committee. Since January 2016 until 2018, member of the ESMO Executive Board of Directors.

Member of the General Medicine Faculty of the School of Medicine, University of Ioannina with organisational, administrative and management duties, since 2010.

Chair, Oncology Committee of the Ioannina University Hospital, since March 2016.

Member, Scientific Committee of Pharmacovigilance and Drugs of the Ioannina University Hospital, since 2010.

Member of the National Committee of Pharmacovigilance, National Drug Agency (EOF) since 2016.

Member of the Task Force for development of Therapeutic Protocols in Gastrointestinal Cancer, EOPPY, Hellenic Ministry of Health, 2017 till currently.

Evaluator of oncology clinical trials for the National Ethics Committee (EED), 2017 till currently.

Member of the Scientific Committee of the Cancer Biobank Centre, University of Ioannina, Greece.

## APPENDIX

(All appear in chronological order)

### A. PUBLICATIONS

1. Effect of 5-fluorouracil infusion in myocardial perfusion scans. *European Journal of Cancer* 1997;33(suppl 8):60  
Bishiniotis T, Mouratidou D, Pentheroudakis G, Andreadis C, Katseas G, Litos A, Hatseras D.  
Theagenion Anticancer Hospital, Thessaloniki, Greece.
2. Non infusional 5Fu, leucovorin and cisplatin combination chemotherapy in the treatment of advanced gastric carcinoma. *Journal of Balkan Union of Oncology and Neurology (BUON)* 2001; 6:23-27.  
C.Andreadis, G.Pentheroudakis, C.Kartsios,L. Sidiropoulos, G.Blatzas, D .Mouratidou.  
Theagenion Anticancer Hospital, Thessaloniki, Greece.
3. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915) a novel E-ring modified camptothecin analogue, in adult patients with solid tumors. *Clinical Cancer Research* 2003;9: 4101-4107.  
Hans Gelderblom, Ramon Salazar, Jaap Verweij, G Pentheroudakis, Maja J,A. de Jonge, Martin Devlin, Christel van Hooije, Francis Seguy, Rosendo Obach, Paola Principe, Chris Twelves. Rotterdam Cancer Institute, Netherlands, Beatson Oncology Centre, Glasgow, UK and Beaufour Ipsen,Paris, France
4. Non infusional 5FU, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. *Acta Oncologica* 2001;Vol 40:7:855-861.  
G.Pentheroudakis, K. Lim, D .Dunlop, M. Soukop, M.Eatock.  
Dept of Medical Oncology, Glasgow Royal Infirmary.
5. Spontaneous acute tumor lysis syndrome in patients with metastatic germ cell tumors: Report of two cases. *Supportive Care in Cancer*. 2001;9: 554-557.  
G.Pentheroudakis, VJ O Neill, P.Vasey, SB Kaye.  
Beatson Oncology Centre, Glasgow, UK.
6. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. *Annals of Oncology* 2002; 13:1469-1478.  
TRJ Evans, G Pentheroudakis,J Paul, A McInnes,R Blackie,N Raby,R Morrison, GM Fullarton, M. Soukop, A. Mc Donald. Beatson Oncology Centre, Glasgow, UK.
7. The rational development of capecitabine from the laboratory to the clinic. *Anticancer Research* 2002; Volume 22,issue 6B: 3589-3596.  
G. Pentheroudakis, C. Twelves.  
Beatson Oncology Centre, Glasgow, UK.
8. Capecitabine ( Xeloda): From the laboratory to the patient's home. *Clinical Colorectal Cancer*, 2002;2(1): 16-23.  
G. Pentheroudakis, C. Twelves.  
Beatson Oncology Centre, Glasgow, UK.

9. A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience. *UroOncology*, 2002; 2(4): 179-184.  
E. Briasoulis, G. Pentheroudakis, I. Letsa, N. Pavlidis.  
Department of Medical Oncology, Ioannina University Hospital, Greece.
10. Immunomodulation in colorectal cancer: disappointment or promise? *Annals of Oncology* 2003; 14:349-351.  
G. Pentheroudakis, N. Pavlidis.  
Department of Medical Oncology, Ioannina University Hospital, Greece.
11. Pregnancy and cancer. *Forum of Clinical Oncology* 2003; Vol 2(1):20-30.  
G. Pentheroudakis, N. Pavlidis.  
Oncology Clinic of Ioannina University Hospital.
12. Improved prognosis of patients with intermediate and poor risk non seminomatous germ cell tumors by optimizing combined modality treatment. *British Journal of Urology*, 2003;92(1):36-42.  
G.Pentheroudakis, JS de Bono, A. Simpson, M.Mackean, P.Vasey, SB Kaye, D. Kirk.  
Beatson Oncology Centre, Glasgow, UK.
13. Concurrent primary peritoneal cancer, ovarian type and peritoneal choriocarcinoma: A case report. *Gynecologic Oncology* 2004;92(2):697-700.  
G. Pentheroudakis, P.Vasey, J.Davies.  
Beatson Oncology Centre, Glasgow, UK.
14. Optimal operational and adjuvant therapy in locoregional gastric cancer patients. *Forum of Clinical Oncology* 2003;2(B):126-132.  
G. Pentheroudakis.  
Oncology Clinic of Ioannina University Hospital.
15. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. *Chemotherapy*, 2005;51(2/3): 154-161.  
G. Pentheroudakis, E. Briasoulis, V. Karavassilis, D. Mauri, E. Tzamakou, D. Rammou, N. Pavlidis.  
Department of Medical Oncology, University Hospital of Ioannina, Greece.
16. Juvenile Cancer: Improving cancer care for adolescents and young adults within the frame of Medical Oncology. *Annals of Oncology* 2005; 16:2-188.  
G. Pentheroudakis, N. Pavlidis.  
Department of Medical Oncology, University Hospital of Ioannina, Greece.
17. Cavitating lung cancer: distinct entity or not? *Lung Cancer* 2004;45(3):349-55.  
G. Pentheroudakis, L. Kostadima, G. Fountzilias , A. Kalogera-Fountzila, D. Skarlos, C. Kalofonos, N. Pavlidis.  
HECOG, Greece.

18. Evidence-based Oncology. *Annals of Oncology* 2004; 15:361-362.  
G. Pentheroudakis, N. Pavlidis.  
Dept of Medical Oncology, Ioannina University Hospital, Greece.
19. Phase I trial of weekly paclitaxel combined with four-weekly pegylated liposomal doxorubicin in patients with advanced solid tumors: a dose-escalating and pharmacokinetic study. *Annals of Oncology* 2004; 15:1566-1573.  
E. Briasoulis, G. Pentheroudakis, V. Karavassilis, O. Siarabi, N. Pavlidis.  
Department of Medical Oncology, University Hospital of Ioannina, Greece.
20. Urinary test use for cancer screening: An underestimated health economics pitfall? *Journal of Laboratory and Clinical Medicine*, 2004;143(6):366-67.  
C. Panou, P. Alevizaki, D. Mauri, A. Ioakimidou, A. Vittoraki, A. Spiliopoulou, D. Chasioti, E. Loukidou, G. Kouris, G. Pentheroudakis.
21. Phase I study of biweekly 24 hour infusion of irinotecan followed by 1 hour docetaxel infusion in patients with chemorefractory malignancies. *AntiCancer Drugs* 2004;15(8):747-752.  
E. Briasoulis, G. Pentheroudakis, H. Timotheadou, G. Foutzilas, N. Pavlidis.  
Departments of Medical Oncology, Ioannina University Hospital, AXEPA University Hospital, Greece.
22. The neutrophil, not the tumor: CA 15-3 increase in breast cancer patients on GCSF-primed adjuvant chemotherapy as a result of GCSF-induced neutrophil overexpression of MUC1. *Cancer* 2004;101(8):1767-1775.  
G. Pentheroudakis, K. Damala, A. Vassou, G. Vartholomatos, N. Kolaitis, E. Briasoulis, V. Malamou-Mitsi, N. Pavlidis. Ioannina University Hospital.
23. Chemotherapy in patients with favorable subsets of unknown primary carcinoma: active, but how effective? *Acta Oncologica* 2005;44:155-60.  
G. Pentheroudakis, E. Briasoulis, V. Karavassilis, G. Fountzilas, N. Xeros, G. Samelis, N. Samantas, N. Pavlidis., HECOG.
24. Juvenile Oncology: Improving the treatment and outcome of adolescents and young adults with cancer. *Forum of Clinical Oncology* 2004;3(3/4):168-182.  
G. Pentheroudakis, P. Kourakos, N. Pavlidis.  
Oncology Clinic of Ioannina University Hospital.
25. Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation. *Urologic Oncology* 2005;23:318-22.  
Davide Mauri, Georgios Pentheroudakis, Christos Tolis, Marzanna Chojnacka, Nicholas Pavlidis.  
Dept of Medical Oncology, Ioannina University Hospital.
26. Management of leptomeningeal malignancy.  
*Expert Opinion in Pharmacotherapy* 2005;6(7):1115-1125.  
G. Pentheroudakis, N. Pavlidis.  
Dept of Medical Oncology, Ioannina University Hospital.



27. The pregnant mother with breast cancer: Diagnostic and therapeutic management. *Cancer Treatment Reviews* 2005;31(4):439-447.  
N. Pavlidis, G. Pentheroudakis.  
Dept of Medical Oncology, Ioannina University Hospital.
28. Adolescent and Young Adult Oncology: Optimistic perspective and considerations. *What's new in Rheumatology*, Ed. Iatriki Paideia, 2005;2(12):11  
G. Pentheroudakis.
29. Paclitaxel/Carboplatin in patients with advanced breast cancer: The HECOG experience and review of the literature. *Medical Oncology* 2006;23(2):147-160.  
G. Pentheroudakis, E. Razi, A. Athanassiadis, N. Pavlidis, G. Fountzilias.  
HECOG.
30. Cancer and Pregnancy: Poena Magna, not anymore. *European Journal of Cancer* 2006;42(suppl 2):126-140.  
G. Pentheroudakis, N. Pavlidis.  
Dept of Medical Oncology, Ioannina University Hospital.
31. Treatment of colorectal cancer in the elderly: a review of the literature. *Cancer Treatment Reviews* 2006;32:1-8.  
V. Golfinouopoulos, G. Pentheroudakis, N. Pavlidis.  
Dept of Medical Oncology, Ioannina University Hospital.
32. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. *Breast Cancer Research and Treatment* 2005;97:237-44  
George Pentheroudakis, George Fountzilias, Dimitrios Bafaloukos, Vasiliki Koutsoukou, Dimitrios Pectasides, Dimosthenis Skarlos, Epaminondas Samantas, Haralabos P. Kalofonos, Helen Gogas, Nicholas Pavlidis.  
Hellenic Cooperative Oncology Group (HECOG), Greece.
33. Non small cell lung cancer in the young: different from elderly counterparts? Retrospective analysis of diagnosis, management and outcome data of 1906 patients. *Anticancer Research* 2006;26:3175-81.  
D.Mauri, G. Pentheroudakis, D. Bafaloukos, D. Pectasides, E. Samantas, E. Efsthathiou, H.P. Kalofonos, K. Syrigos, G. Klouvas, P. Papakostas, P. Kosmidis, G. Fountzilias, N. Pavlidis.  
Hellenic Cooperative Oncologic Group (HeCOG), Greece.
34. Elderly patients with squamous lung carcinoma: Faring better or worse? *Supportive Care in Cancer* 2006;14(8):867-70.  
G. Pentheroudakis, K. Neanidis, L. Kostadima, G. Fountzilias, N. Pavlidis. HECOG.
35. Colorectal cancer screening awareness in European primary care. *Cancer Detection and Prevention* 2006;30:75-82.  
Davide Mauri MD, George Pentheroudakis MD, Athanasios Milousis MD, Apostolos Xilomenos MD, Evaggelia Panagouloupoulou MD, Magdalini Bristianou MD, Georgios Zacharias MD, Dimitrios Christidis MD, Evaggelia Aikaterini Mustou MD, Athanasia Gkinosati MD, Nicholas Pavlidis MD. University of Ioannina.

36. Survivin and glycodelin mRNA expression in early breast cancer: Expression of two key regulators of cell cycle in 272 women with breast cancer. *Breast Cancer Research and Treatment* 2006;100(2):161-7.  
L. Kostadima, G. Pentheroudakis, N. Pavlidis, et al. HECOG.
37. Juvenile Oncology: A missing subspecialty. The experience of a reference cancer centre. *Journal of Clinical and Translational Oncology* 2006;8:444-9.  
G. Pentheroudakis, D. Mauri, L. Kostadima, V. Golfinopoulos, G. Alexiou, A. Karakatsanis, N. Pavlidis.  
Department of Medical Oncology, University Hospital of Ioannina, Greece.
38. Old habits die hard: Chest radiography for screening purposes in primary care. *American Journal of Managed Care* 2006;12:650-6.  
Davide Mauri, Konstantinos Kamposioras, Anastasios Proiskos, Apostolos Xilomenos, Christina Peponi, Mario Dambrosio, Georgios Zacharias, Georgios Koukourakis, George Pentheroudakis, Nicholas Pavlidis.
39. Perspectives for targeted therapy in cancer of unknown primary site. *Cancer Treatment Reviews* 2006;32:637-44.  
G.Pentheroudakis, N. Pavlidis.
40. Late toxicity in survivors from adolescent cancers. *Cancer Treatment Reviews* 2007;33:656-63.  
G.Pentheroudakis, N. Pavlidis.
41. Cancer of unknown primary site: Missing primary or missing biology? *The Oncologist* 2007;12:418-25.  
George Pentheroudakis, Evangelos Briasoulis, Nicholas Pavlidis.
42. C-KIT PDGFR mutational analysis and tissue expression in a cohort of 50 patients with cancer of unknown primary. *Journal of Cancer Research and Clinical Oncology* 2008;134(6):697-704.  
L. Dova, G. Pentheroudakis, G. Vartholomatos, I. Georgiou, V. Malamou-Mitsi, E. Briasoulis, G.Fountzilias, A. Ntemou, N. Pavlidis.
43. Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target? *Clinical and Experimental Metastasis* 2007;24(2):79-86.  
L. Dova, G. Pentheroudakis, I. Georgiou, V. Malamou-Mitsi, G. Vartholomatos, G. Fountzilias, N. Kolaitis, E. Kitsiou, N. Pavlidis.
44. A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed by oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC). *Journal of clinical oncology*,24(18):3583,Part1,Suppl.S,JUN20:2006  
Kalofonos HP, Papakostas P, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis ITsavdaridis D, Syrigos K, Kosmidis P, Fountzilias G.
45. Weekday on- weekend off oral capecitabine: a phase I study of a continuous schedule

better simulating protracted fluoropyrimidine therapy. *Cancer Chemotherapy and Pharmacology*, 2007;60(5):733-9

G.Pentheroudakis, P. Pappas, V. Golfopoulos, G. Fountzilas, M. Nikolaidou, V. A. Boumba, T. Vougiouklakis, L. Nikiforidis, E. Tzamakou, O. Siarabi, M. Marselos, N. Pavlidis.

46. Oncology for Medical Students: a European School of Oncology contribution to undergraduate

cancer education. *Cancer Treatment Reviews*, 2007;33:419-26

N. Pavlidis, J.B. Vermorcken, R. Stahel, J. Bernier, A. Cervantes, R. Audisio, G. Pentheroudakis, A. Costa.

47. Switching benchmarks in cancer of unknown primary: from autopsy to microarray.

*European Journal of Cancer* 2007;43:2026-36

G.Pentheroudakis, V. Golfopoulos, N. Pavlidis.

48. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer:

Accumulating evidence of efficacy, synergy and safety. *Crit Rev Oncol/Hematol* 2008; 66(1):31-41

G.Lazaridis, G. Pentheroudakis, N. Pavlidis.

49. The missing kiss of life: transcriptional activity of the metastasis-suppressor gene

KiSS1 in early breast cancer. *Anticancer Research* 2007;27:2499-2504.

L. Kostadima, G. Pentheroudakis, N. Pavlidis.

50. Can circulated lung cancer cells pass to the urine without apparent urine tract metastases? A single centre series. *Lung Cancer* 2008;60:141-5.

K. Kambosioras, G. Pentheroudakis, V. Malamou-Mitsi, L. Pappa, M. Bafa, N. Pavlidis.

51. Biological identity data retrospect of Cancer of Unknown Primary.

*Forum of Clinical Oncology* 2007;6: 106-15.

E. Voulgaris, G. Pentheroudakis, E. Briasoulis, N. Pavlidis.

52. Systemic dissemination in cancer of unknown primary is independent of mutational inactivation

of the KiSS1 metastasis-suppressor gene. *Pathology Oncology Research* 2008;14:239-41

L. Dova, G. Pentheroudakis, V. Golfopoulos, I. Georgiou, N. Pavlidis.

53. Palliative chemotherapy in elderly patients with common metastatic malignancies:

A HeCOG registry analysis of management, outcome and clinical benefit predictors. *Critical Reviews in Oncology and Hematology* 2008;66:237-47.

George Pentheroudakis, George Fountzilas, Haralambos P Kalofonos, Vassilios Golfopoulos, Gerasimos Aravantinos, Dimitrios Bafaloukos, Pavlos Papakostas, Dimitrios Pectasides, Christos Christodoulou, Konstantinos Syrigos, Theofanis Economopoulos, Nicholas Pavlidis.

54. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre HeCOG phase II study. *Acta Oncologica* 2008;47:1148-55 .

G. Pentheroudakis, E. Briasoulis, H.P. Kalofonos, G. Fountzilas, T. Economopoulos, G. Samelis, A. Koutras, M. Karina, N. Xiros, E. Samantas, A. Bamias, N. Pavlidis.

55. Gastrointestinal, urologic and lung malignancies during pregnancy. *Recent Results Cancer Res.* 2008;178:137-64.

G.Pentheroudakis, N. Pavlidis.

56. Metastatic involvement of placenta and foetus in pregnant women with cancer. *Recent Results Cancer Res.* 2008;178:183-94.

G.Pentheroudakis, N. Pavlidis.

57. Donor-derived breast cancer in a bone marrow transplantation recipient. *Breast Cancer Research and Treatment* 2008; DOI: 10,1007/s10549-008-9922-7 , 2/9/08.

V. Golfopoulos, G. Pentheroudakis, S. Kamakari, V. Metaxa-Mariatou, N. Pavlidis.

58. Cancer, Fertility and Pregnancy. ESMO Clinical recommendations for diagnosis, treatment and follow-up. *Annals of Oncology* 2008;19(suppl 2):ii108-109.

G. Pentheroudakis, N. Pavlidis, M. Castiglione.

59. Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: A matched controlled study. *Breast J.* 2009 Sep-Oct;15(5):461-7

Michael J. Halaska , George Pentheroudakis , Pavel Strnad , Hana Stankusova , Jiri Chod Helena Robova , Lubos Petruzela , Lukas Rob , Nicholas Pavlidis.

60. Liver metastases from Cancer of Unknown Primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. *Cancer Treatment Reviews* 2008; 34:693-700

George Lazaridis, George Pentheroudakis, Nicholas Pavlidis.

61. Cancer and Pregnancy. *Annals of Oncology* 2008;19(suppl 5):v38-39.

George Pentheroudakis.

62. Prognosis in Advanced Cancer. *Surgical Oncology* (2008), doi:10,1016/j.suronc.2008.06,007

George Pentheroudakis

63. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. *Breast Cancer Research and Treatment* 2009;116:131-143.

George Pentheroudakis, Konstantine T. Kalogeras, Ralph M. Wirtz, Irene Grimani, George Zografos, Helen Gogas, Udo Stropp, Dimitrios Pectasides, Dimosthenis Skarlos, Guido Hennig, Epaminondas Samantas, Dimitrios Bafaloukos, Pavlos Papakostas, Haralabos P. Kalofonos, Nicholas Pavlidis, George Fountzilas.

64. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study. *Eur J Cancer* 2008, July 16; In press, DOI: 10,1016/j.ejca.2008.05,025

Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E, Karina M, Misailidou D, Pisanidis N, Pentheroudakis G, Economopoulos T, Papadimitriou C, Skarlos DV, Pectasides D, Stavropoulos M, Bafaloukos D, Kardamakis D, Karanikiotis C, Vourli G, Fountzilas G. HECOG.

65. Heterogeneity in cancer guidelines: should we eradicate or tolerate? *Annals of Oncology* 2008;19:2067-78.

G. Pentheroudakis, R. Stahel, H. Hansen, N. Pavlidis.  
European Society of Medical Oncology Guidelines Working Group.

66. Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): Report of a case and review of the literature.

E. Voulgaris, G. Pentheroudakis, A. Vassou, N. Pavlidis.  
*Lung Cancer* 2009;64:247-49

67. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review

George Pentheroudakis , F.A. Greco , Nicholas Pavlidis .  
*Cancer Treatment Reviews* 2009;35:221-7.

68. Cancer of unknown primary: What kind of chemotherapy? What kind of disease?

G Pentheroudakis, N Pavlidis.  
*Onkologie* 2009;32:159-60.

69. A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer.

G. Pentheroudakis<sup>1</sup>, L. Kostadima<sup>1</sup>, L. Dova<sup>2</sup>, I. Georgiou<sup>3</sup>, T. Tzavaras<sup>4</sup>,  
G. Vartholomatos<sup>2</sup>, R.M. Wirtz<sup>5</sup>, G. Fountzilas<sup>6</sup>, V. Malamou-Mitsi<sup>7</sup>,  
N. Pavlidis  
*Neoplasma*. 2010;57(1):47-54..

70. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favorable prognosis subset of patients with CUP.

Pavlidis N, Pentheroudakis G, Plataniotis G.  
*Clinical and Translational Oncology* 2009;11:340-8.

71. Cancer of unknown primary: what kind of chemotherapy? What kind of disease?

Pentheroudakis G, Pavlidis N.  
*Onkologie*. 2009 Apr;32(4):159-60

72. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: Multiple-treatments meta-analysis.

Golfinoopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N.  
*Cancer Treatment Reviews* 2009;35:570-3.

73. Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group.

Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilias G.  
Oncology. 2009 Jul 21;77(2):107-112.

74. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilias G.  
BMC Cancer. 2009 Sep 24;9(1):339

75. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence.

Pentheroudakis G, Lazaridis G, Pavlidis N.  
Breast Cancer Res Treat 2010;119:1-11

76. Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome.

Pentheroudakis G, Angouridakis N, Wirtz R, Nikolaou A, Kalogeras KT, Pavlidis N, Fountzilias G. J Oncol. 2009;2009:854127. Epub 2009 Oct 7.

77. Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.

Koumarianou A, Fountzilias G, Kosmidis P, Klouvas G, Samantas E, Kalofonos C, Pentheroudakis G, Economopoulos T, Pectasides D.  
J Chemother. 2009 Nov;21(5):573-83.

78. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.

Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou C, Pentheroudakis G, Pectasides D, Dimopoulos MA, Fountzilias G.  
Cancer Chemother Pharmacol. 2010 Feb 4. [Epub ahead of print]PMID: 20130877

79. Probing the unknown in cancer of unknown primary: which way is the right way?

Pentheroudakis G, Pavlidis N.  
Ann Oncol. 2010 Jan 20. [Epub ahead of print].

80. Serous papillary peritoneal carcinoma: Unknown primary tumor, ovarian cancer counterpart or a distinct entity? A systematic review.

Pentheroudakis G, Pavlidis N.  
Crit Rev Oncol Hematol. 2009 Nov 6. [Epub ahead of print]PMID: 19897383

81. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature.

Kamposioras K, Pentheroudakis G, Pectasides D, Pavlidis N.  
Crit Rev Oncol Hematol 2011;78:112-126

82. High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.

Pentheroudakis G, Goussia A, Voulgaris E, Nikolaidis K, Ioannidou E, Papoudou-Bai A, Grepis K, Kanavaros P, Pavlidis N, Bai M.  
Leuk Lymphoma. 2010 Jul;51(7):1260-8.PMID: 20497003

83. Undergraduate training in oncology: An ESO continuing challenge for medical students.  
Pavlidis N, Vermorken JB, Stahel R, Bernier J, Cervantes A, Pentheroudakis G, Audisio RA, Costa A.  
Surg Oncol. 2010 Aug 12. [Epub ahead of print] PMID: 20708925

84. Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).  
Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, Dimopoulos MA, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S, Katirtzoglou N, Bakogiannis C, Syrigos KN. Ann Oncol. 2011;22:827-34

85. Cancer of unknown primary site: 20 questions to be answered.  
Pavlidis N, Pentheroudakis G.  
Ann Oncol. 2010 Oct;21 Suppl 7:vii303-vii307

86. Kalofonos HP, Papakostas P, Makatsoris T, Papamichael D, Vourli G, Xanthakis I, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis I, Samelis G, Syrigos KN, Xiros N, Stavropoulos M, Kosmidis P, Christodoulou C, Linardou H, Skondra M, Pectasides D, Economopoulos T, Fountzilas G.  
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.  
Anticancer Res. 2010 Oct;30(10):4325-33.  
PMID: 21036759

87. Voulgaris E, Pentheroudakis G, Pappa L, Bafa M, Goussia A, Dalezis P, Tsombanidou C, Geromichalos G, Papageorgiou A, Koutsilieris M, Malamou-Mitsi V, Pavlidis N.  
Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases.  
Lung Cancer. 2011 Jul;73(1):51-8

88. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  
Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N; ESMO Guidelines Working Group.  
Ann Oncol. 2010 May;21 Suppl 5:v266-73

89. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  
Pavlidis N, Briasoulis E, Pentheroudakis G; ESMO Guidelines Working Group.  
Ann Oncol. 2010 May;21 Suppl 5:v228-31

90. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.  
Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group.  
Ann Oncol. 2010 May;21 Suppl 5:v214-9

91. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G; ESMO Guidelines Working Group. *Ann Oncol.* 2010 May;21 Suppl 5:v194-7
92. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. *Ann Oncol.* 2010 May;21 Suppl 5:v190-3
93. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G. *BMC Med.* 2011 Jan 31;9(1):10. [Epub ahead of print]
94. Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer. Pentheroudakis G, Stoyianni A. *Curr Med Chem.* 2011;18(11):1629-39
95. Prognostic utility of  $\beta$ -tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. *Breast Cancer Res Treat.* 2011 May;127(1):179-193.
96. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Stoyianni A, Pentheroudakis G, Pavlidis N. *Cancer Treat Rev.* 2011 Aug;37(5):358-65.
97. Paclitaxel and Bevacizumab as First Line Combined Treatment in Patients with Metastatic Breast Cancer: The Hellenic Cooperative Oncology Group Experience with Biological Marker Evaluation. Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM.



Anticancer Res. 2011 Sep;31(9):3007-3018.

98. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G; ESMO Guidelines Working Group. *Ann Oncol.* 2011 Sep;22 Suppl 6:vi64-8.

99. Profiling clinical cancer research across the Atlantic: A review of research and its characteristics presented at ASCO and ESMO Congresses during the last decade.

Pentheroudakis G, Krikelis D, Cervantes A, Vermorken J, Pavlidis N. *Cancer Treat Rev.* 2012 Oct;38(6):560-5.

100. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P.

*J Transl Med.* 2012 Jan 12;10(1):10.

101. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.

Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G.

*Breast Cancer Res Treat.* 2012 (134):353-62

102. Pavlidis N, Pentheroudakis G.

Cancer of unknown primary site.

*Lancet.* 2012 Apr 14;379(9824):1428-35.

103. Pavlidis N, Petrakis D, Golfinopoulos V, Pentheroudakis G.

Long-term survivors among patients with cancer of unknown primary.

*Crit Rev Oncol Hematol.* 2012 Oct;84(1):85-92

104. Pentheroudakis G, Nicolaou I, Kotoula V, Fountzilas E, Markou K, Eleftheraki AG, Fragkoulidi A, Karasmanis I, Tsigka A, Angouridakis N, Vlachtsis K, Nikolaou A, Pavlidis N, Fountzilas G.

Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx.

*Oral Oncol.* 2012 Aug;48(8):709-16.

105. Boussios S, Pentheroudakis G, Kamina S, Katsanos K, Pavlidis N.

Docetaxel-induced enterocolitis: a serious and potentially fatal adverse event.

*J BUON.* 2011 Oct-Dec;16(4):778-9.

106. Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.

Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N. *Clin Exp Metastasis Clin Exp Metastasis*. 2012 Aug;29(6):603-14.

107. Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.  
Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, Golfopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N.  
*Anticancer Res*. 2012 Apr;32(4):1273-81.

108. Bevacizumab in ovarian cancer.  
Mountzios G, Pentheroudakis G.  
*N Engl J Med*. 2012 Mar 29;366(13):1257-58.

109. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.  
Pectasides D, Papaxoinis G, Kalogeras K, Eleftheraki A, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G.  
*BMC Cancer*. 2012 Jun 29;12(1):271.

110. Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.  
Golfopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, Cervantes A, Ciuleanu T, Marselos M, Fountzilas G, Malamou-Mitsi V, Pavlidis N.  
*Annals of Oncology* 23: 2725–2730, 2012

111. Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.  
Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N.  
*Clin Exp Metastasis*. 2012 Aug;29(6):603-14.

112. Prognosis of pregnancy-associated breast cancer: A meta-analysis of 30 studies.  
Azim HA Jr, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA.  
*Cancer Treat Rev*. 2012 Nov;38(7):834-42.

113. CUP: looking for a missing primary site and its biology  
G. Pentheroudakis  
*Annals of Oncology* 2012 23: x278-x281

114. ESMO Consensus Conferences: another source of ESMO Clinical Practice Guidelines  
N. Pavlidis, R. Stahel, G. Pentheroudakis, A. Cervantes, and on behalf of the ESMO Guidelines Working Group  
*Ann Oncol*. 2012 Oct;23 Suppl 7:vii7-10.

115. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  
R. Dummer, A. Hauschild, M. Guggenheim, U. Keilholz, G. Pentheroudakis, on behalf of the ESMO Guidelines Working Group  
Ann Oncol 2012 23:vii86-vii91.
116. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  
F. Pacini, M. G. Castagna, L. Brilli, G. Pentheroudakis, and on behalf of the ESMO Guidelines Working Group  
Ann Oncol 2012 23:vii110-vii119.
117. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up  
A. Berruti, E. Baudin, H. Gelderblom, H. R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis, and on behalf of the ESMO Guidelines Working Group  
Ann Oncol 2012 23:vii131-vii138.
118. Clinical trials in oncology: a comprehensive scientific, ethical, legal and financial overview  
George Pentheroudakis, Ilias Kotteas, Dimitris Mavroudis, Epameinondas Samantas, Gerasimos Aravantinos, Nikos Maniadas, Eleni Efstathiou, Dimitrios Pectasides  
Forum of Clinical Oncology 2012; 3(4):9-13
119. Topoisomerase ii alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.  
Fountzilias G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumariou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT.  
J Transl Med. 2012 Oct 23;10(1):212.
120. Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.  
Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V, Fountzilias G, Sanden M, Pavlidis N, Benjamin H, Aharonov R.  
Clin Exp Metastasis. 2013 Apr;30(4):431-9.
121. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilias G.  
BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49.

122. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.

Karavasilis V, Kotoula V, Pentheroudakis G, Televantou D, Lambaki S, Chrisafi S, Bobos M, Fountzilias G.

J Neurol. 2013 Jun;260(6):1469-80.

123. Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. Stavropoulou AV, Fostira F, Pertesi M, Tsiplaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos MA, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, Aravantinos G, Karydakias V, Yannoukakos D, Fountzilias G, Konstantopoulou I.

PLoS One. 2013;8(3):e58182. doi: 10.1371/journal.pone.0058182.

124. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks.

Kamposioras K, Pentheroudakis G, Pavlidis N.

Eur J Clin Invest. 2013 May;43(5):491-500.

125. Cancer of Unknown Primary Site:

The Pathologist's Point of View.

Anna Batistatou, George Pentheroudakis, Nicholas Pavlidis.

TJOP 2013;00:1–8

126. Prognostication in cancer of unknown primary (CUP): Development of a prognostic algorithm in 311 cases and review of the literature. Petrakis D, Pentheroudakis G, Voulgaris E, Pavlidis N.

Cancer Treat Rev. 2013 Nov;39(7):701-8.

127. Anti-Angiogenesis in Cancer Therapy: Hercules And Hydra.

Bellou S, Pentheroudakis G, Murphy C, Fotsis T.

Cancer Lett. 2013 Sep 28;338(2):219-28.

128. Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G; on behalf of the ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2013 Oct;24 Suppl 6:vi160-70. doi: 10.1093/annonc/mdt199.

129. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary.

Pentheroudakis G, Pavlidis N, Fountzilias G, Krikelis D, Goussia A, Stoyianni A, Sanden M, St Cyr B, Yerushalmi N, Benjamin H, Meiri E, Chajut A, Rosenwald S, Aharonov R, Spector Y.

Mol Cancer. 2013 Jun 10;12:57. doi: 10.1186/1476-4598-12-57

130. Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling.

A. Stoyianni, G. Pentheroudakis, H. Benjamin, A. Cervantes, K. Ashkenazi, G Lazaridis, N. Pavlidis, Y. Spector.

Clinical Translational Oncology, 2013.

SpringerLink:

<http://www.springerlink.com/openurl.asp?genre=article&id=doi:10.1007/s12094-013-1139-5>, DOI 10.1007/s12094-013-1139-5

131. Bevacizumab and micrometastases: Revisiting the preclinical and clinical rollercoaster. Mountzios G, Pentheroudakis G, Carmeliet P. *Pharmacol Ther.* 2014 Feb;141(2):117-24. doi: 10.1016/j.pharmthera.2013.09.003.
132. The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab. Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatsas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G. *Clin Colorectal Cancer.* 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17. PubMed PMID: 24050852.
133. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. Fountzilas G, Kotoula V, Pectasides D, Kouvatsas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, Skarlos DV. *PLoS One.* 2013 Jul 23;8(7):e69256. doi: 10.1371/journal.pone.0069256. Print 2013. PubMed PMID: 23935969.
134. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). Pentheroudakis G, Kotoula V, Eleftheraki AG, Tsolaki E, Wirtz RM, Kalogeras KT, Batistatou A, Bobos M, Dimopoulos MA, Timotheadou E, Gogas H, Christodoulou C, Papadopoulou K, Efstratiou I, Scopa CD, Papaspyrou I, Vlachodimitropoulos D, Linardou H, Samantas E, Pectasides D, Pavlidis N, Fountzilas G. *PLoS One.* 2013 Jul 29;8(7):e70634. doi: 10.1371/journal.pone.0070634. Print 2013. PubMed PMID: 23923010.
135. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatsas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. *BMC Cancer.* 2014 Feb 20;14(1):111. [Epub ahead of print] PubMed PMID: 24555920.
136. Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Lazaridis G, Lambaki S, Karayannopoulou G, Eleftheraki AG, Papaspiroiu I, Bobos M, Efstratiou I, Pentheroudakis G, Zamboglou N, Fountzilas G. *Strahlenther Onkol.* 2014 Mar 22. [Epub ahead of print] PubMed PMID: 24658605.

137. Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes.

Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatsas G, Timotheadou E, Zebekakis P, Efstratiou I, Gogas H, Vamvouka C, Chrisafi S, Stofas A, Pentheroudakis G, Koutras A, Galani E, Bafaloukos D, Fountzilas G.

PLoS One. 2014 Mar 17;9(3):e91407. doi: 10.1371/journal.pone.0091407.

eCollection 2014. PubMed PMID: 24637962; PubMed Central PMCID: PMC3956672.

138. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.

Razis E, Pentheroudakis G, Rigakos G, Bobos M, Kouvatsas G, Tzaida O, Makatsoris T, Papakostas P, Bai M, Goussia A, Samantas E, Papamichael D, Romanidou O, Efstratiou I, Tsolaki E, Psyrri A, De Roock W, Bafaloukos D, Klouvas G, Tejpar S, Kalogeras KT, Pectasides D, Fountzilas G.

J Cancer Res Clin Oncol. 2014;140(5):737-48.

139. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide

Evangelia Peponi, Ioannis Tourkantonis, Ifigenia Tasiou, Nicholas Pavlidis, George Pentheroudakis, Periklis Tsekeris. J BUON 2014; 19:3, In Press

140. Development of a low grade lymphoma in the mastoid bone in a patient with atypical Cogans syndrome: A case report

Chris Kalogeropoulos, Dimitrios Karachalios, George Pentheroudakis, Aikaterini Tsikou-Papafrangou, Lydia Abou-Asabeh, Maria Argyropoulou, Alexandros Drosos, Nicholas Pavlidis

Journal of Advanced Research, DOI information: 10.1016/j.jare.2014.05.003

141. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review

Dimitrios Petrakis , George Pentheroudakis , Sevasti Kamina , Lambrini Pappa , Evangelos Papadiotis , Vassiliki Malamou-Mitsi , Nicholas Pavlidis

Journal of Advanced Research, DOI information:10.1016/j.jare.2014.05.002

142. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G; on behalf of the ESMO Guidelines Working Group.

Ann Oncol. 2014 Apr 29. [Epub ahead of print] PubMed PMID: 24782454.

143. The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.

Lakis S, Kotoula V, Eleftheraki AG, Batistatou A, Bobos M, Koletsa T, Timotheadou E, Chrisafi S, Pentheroudakis G, Koutras A, Zagouri F, Linardou H, Fountzilas G.

Breast. 2014 Jun;23(3):234-43. doi:10.1016/j.breast.2014.02.013. Epub 2014 Apr 3. PubMed PMID: 24703723.

144. Association of VEGF-A Splice Variant mRNA Expression

With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, Dimopoulos MA, Papandreou CN, Fountzilas G.

Clin Breast Cancer. 2014 Mar 1. pii: S1526-8209(14)00034-2. doi:

10.1016/j.clbc.2014.02.009. [Epub ahead of print] PubMed PMID: 24703319.

145. Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management.

Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N.

Ann Gastroenterol. 2012;25(2):106-118. Review. PubMed PMID: 24713845;

PubMed Central PMCID: PMC3959393.

146. A patient with neuroendocrine carcinoma of the urinary bladder and paraneoplastic degenerative parencephalitis: A case report and review of the literature

Fotopoulos G, Pentheroudakis G, Ioakeim E, Pavlidis N.

Cancer Treatment Communications, Volume 2, Issue 1 , Pages 8-11, 2014

147. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in Cancer of Unknown Primary: a retrospective study of the Hellenic Cooperative Oncology Group.", has been accepted for publication in Clinical & Experimental Metastasis.

Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N.

Clinical Experimental Metastases, doi:10.1007/s10585-014-9666-1.

148. alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.

Triantafyllia Koletsa, Flora Stavridi, Mattheos Bobos, Ioannis Kostopoulos, Vassiliki Kotoula, Anastasia G Eleftheraki , Irene Konstantopoulou, Christos Papadimitriou, Anna Batistatou, Helen Gogas, Angelos Koutras, Dimosthenis V Skarlos , George Pentheroudakis, Ioannis Efstratiou , Dimitrios Pectasides, George Fountzilas.

BMC Clinical Pathology 2014, 14:28 doi:10.1186/1472-6890-14-28

149. In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients.  
 PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014. PMID: 24968015  
 Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.
150. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a consensus position paper  
 P. G. Casali<sup>1\*</sup>, P. Bruzzi<sup>2</sup>, J. Bogaerts<sup>3</sup>, J.-Y. Blay<sup>4</sup> on behalf of the Rare Cancers Europe (RCE) Consensus Panel  
 Annals of Oncology, 2014, in press.
151. p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab.  
 Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G.  
 Pathol Oncol Res. 2014 Aug 8. [Epub ahead of print] PubMed PMID: 25098276.
152. Comparative Observational Study of Two Ethnic Population Groups of Patients with Hepatocellular Carcinoma  
 George Fotopoulos, Noha Rashad, George Pentheroudakis, Fatma Aboukassem, Hussein Khaled and Nicholas Pavlidis.  
 J Clin Exp Oncol 2014, 3:3  
<http://dx.doi.org/10.4172/2324-9110.1000129>
153. Fountas A, Tigas S, Giotaki Z, Petrakis D, Pentheroudakis G, Tsatsoulis A. Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment. Hormones (Athens). 2014 Dec 29. doi: 10.14310/horm.2002.1560. [Epub ahead of print] PubMed PMID: 25553766.
- 154: Giannoulis DK, Gantsos A, Giotis D, Paschos NK, Vagionas A, Arnaoutoglou CM, Pentheroudakis G, Xenakis TA. Multiple recurrences and late metastasis of adamantinoma in the tibia: a case report. J Orthop Surg (Hong Kong). 2014 Dec;22(3):420-2. PubMed PMID: 25550030.
- 155: Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, Koutras A, Fountzilas G, Maniadas N. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2014 Dec 19. [Epub ahead of print] PubMed PMID: 25524005.



- 156: Boussios S, Pentheroudakis G, Somarakis G, Markatseli TE, Drosos AA, Pavlidis N. Cancer diagnosis in a cohort of patients with Sjogren's syndrome and rheumatoid arthritis: a single-center experience and review of the literature. *Anticancer Res.* 2014 Nov;34(11):6669-76. PubMed PMID: 25368273.
- 157: Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C, Xanthakis I, Kalogeras KT, Basdanis G, Pentheroudakis G, Kotoula V, Fountzilas G. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. *Anticancer Res.* 2014 Sep;34(9):4949-62. PubMed PMID: 25202077.
158. Pectasides D, Karavasilis V, Papaxoinis G, Gourgioti G, Makatsoris T, Raptou G, Vrettou E, Sgouros J, Samantas E, Basdanis G, Papakostas P, Bafaloukos D, Kotoula V, Kalofonos HP, Scopa CD, Pentheroudakis G, Fountzilas G. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer. *BMC Cancer.* 2015 May 10;15(1):384. [Epub ahead of print] PubMed PMID: 25956750.
- 159: Koumarianou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilas G. PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. *Cancer Chemother Pharmacol.* 2015 May 7. [Epub ahead of print] PubMed PMID: 25947084.
160. Linardou H, Pentheroudakis G, Varthalitis I, Gogas H, Pectasides D, Makatsoris T, Fountzilas G, Bafaloukos D; Hellenic Cooperative Oncology Group. Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). *Anticancer Res.* 2015 Feb;35(2):1105-13. PubMed PMID: 25667500.
161. Cervantes A, Pentheroudakis G, Arnold D. Critical evaluation of the scientific content in clinical practice guidelines. *Cancer.* 2015 Jan 29. doi: 10.1002/cncr.29261. [Epub ahead of print] PubMed PMID: 25640148.
162. Economopoulou P, Mountzios G, Pavlidis N, Pentheroudakis G. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. *Cancer Treat Rev.* 2015 May 28. pii: S0305-7372(15)00105-X. doi: 10.1016/j.ctrv.2015.05.010. [Epub ahead of print] Review. PubMed PMID: 26033502.
163. Koutras A, Kalogeras KT, Wirtz RM, Alexopoulou Z, Bobos M, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Pentheroudakis G, Pisanidis N, Magkou C, Christodoulou

C, Bafaloukos D, Papakostas P, Aravantinos G, Pectasides D, Kalofonos HP, Fountzilas G. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. *J Transl Med.* 2015 May 29;13:171. doi: 10.1186/s12967-015-0530-0. PubMed PMID: 26021752; PubMed Central PMCID: PMC4448562.

164. Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial. *PLoS One.* 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015. PubMed PMID: 25970543; PubMed Central PMCID: PMC4430485.

165. Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H, Galani E, Efstratiou I, Zaramboukas T, Koutras A, Aravantinos G, Samantas E, Psyri A, Kourea H, Bobos M, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. *Oncotarget.* 2015 Oct 25. doi: 10.18632/oncotarget.6231. [Epub ahead of print] PubMed PMID: 26506242.

166. Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. *PLoS One.* 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293. eCollection 2015. PubMed PMID: 26452060; PubMed Central PMCID: PMC4599795.

167. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G; ESMO Guidelines Committee. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol.* 2015 Sep;26 Suppl 5:v133-v138. doi: 10.1093/annonc/mdv305. PubMed PMID: 26314775.

168. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol.* 2015 Sep;26 Suppl 5:v126-v132. doi: 10.1093/annonc/mdv297. PubMed PMID: 26314774.

169. Pentheroudakis G, Cardoso F, Arnold D, Sessa C, Peters S, Horwich A, Pavlidis N, Stahel R, Cervantes A; ESMO Guidelines Committee. The ESMO guideline strategy: an identity statement and reflections on improvement. *Ann Oncol.* 2015 Sep;26 Suppl 5:v1-v7. doi: 10.1093/annonc/mdv299. PubMed PMID: 26314771.

170. Fotopoulos G, Gousia A, Baretta E, Koumpis E, Chrisafi S, Bobos M, Malamou-Mitsi V, Fountzilas G, Pavlidis N, Pentheroudakis G. Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary. *Eur J Clin Invest.* 2015 Nov;45(11):1145-52. doi: 10.1111/eci.12518. Epub 2015 Sep 13. PubMed PMID: 26269154.

171. Kalogeropoulos C, Karachalios D, Pentheroudakis G, Tsikou-Papafrangou A, Abou-Asabeh L, Argyropoulou M, Drosos A, Pavlidis N. Development of a low grade lymphoma in the mastoid bone in a patient with atypical Cogan's syndrome: A case report. *J Adv Res.* 2015 May;6(3):523-7. doi: 10.1016/j.jare.2014.05.003. Epub 2014 May 16. PubMed PMID: 26257951; PubMed Central PMCID: PMC4522542.

172. Petrakis D, Pentheroudakis G, Kamina S, Pappa L, Papadiotis E, Malamou-Mitsi V, Pavlidis N. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review. *J Adv Res.* 2015 May;6(3):517-21. doi: 10.1016/j.jare.2014.05.002. Epub 2014 May 17. PubMed PMID: 26257950; PubMed Central PMCID: PMC4522537.

173. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v8-30. doi: 10.1093/annonc/mdv298. PubMed PMID: 26314782.

174. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v78-84. doi: 10.1093/annonc/mdv303. PubMed PMID: 26314781.

175. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v56-68. doi: 10.1093/annonc/mdv295. PubMed PMID: 26314780.

176. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S; ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v40-55. doi: 10.1093/annonc/mdv277. PubMed PMID: 26314779.

177. Kloke M, Cherny N; ESMO Guidelines Committee. Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2015 Sep;26 Suppl 5:v169-73. doi: 10.1093/annonc/mdv306. PubMed PMID: 26314777.
178. Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D, Cardoso F; ESMO Guidelines Committee. Central venous access in oncology: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2015 Sep;26 Suppl 5:v152-68. doi: 10.1093/annonc/mdv296. PubMed PMID: 26314776.
179. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M; ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v116-25. doi: 10.1093/annonc/mdv304. PubMed PMID: 26314773.
180. d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M; ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v108-15. doi: 10.1093/annonc/mdv201. PubMed PMID: 26314772.
181. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v100-7. doi: 10.1093/annonc/mdv200. Epub 2015 Aug 12. PubMed PMID: 26269205.
182. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v85-99. doi: 10.1093/annonc/mdv203. Epub 2015 Aug 4. PubMed PMID: 26242182.
183. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v31-9. doi: 10.1093/annonc/mdv199. Epub 2015 Jul 28. PubMed PMID: 26223247.
184. Parker C, Gillissen S, Heidenreich A, Horwich A; ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v69-77. doi: 10.1093/annonc/mdv222. Epub 2015 Jul 22. PubMed PMID: 26205393.

185. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v139-51. doi: 10.1093/annonc/mdv202. Epub 2015 Jul 4. PubMed PMID: 26142468.
186. Cherny NI, Kloke M, Cervantes A, Pentheroudakis G; ESMO Guidelines Committee. Reply to the letter to the Editor 'How much evidence isn't in evidence-based guidelines?' By Johnson et al. *Ann Oncol*. 2015 Nov 24. pii: mdv583. [Epub ahead of print] PubMed PMID: 26602775.
187. Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. *Clin Colorectal Cancer*. 2015 Nov 11. pii: S1533-0028(15)00144-9. doi: 10.1016/j.clcc.2015.10.005. [Epub ahead of print] PubMed PMID: 26702772.
188. Cherny NI, Kloke M, Cervantes A, Pentheroudakis G; ESMO Guidelines Committee. Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al. *Ann Oncol*. 2015 Nov 24. pii: mdv583. [Epub ahead of print] PubMed PMID: 26602775.
189. Xynos E, Gouvas N, Triantopoulou C, Tekkis P, Vini L, Tzardi M, Boukovinas I, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pentheroudakis G, Pilpilidis I, Sgouros J, Vassiliou V, Xynogalos S, Ziras N, Karachaliou N, Zoras O, Agalianos C, Souglakos J; [the Executive Team on behalf of the Hellenic Society of Medical Oncology (HeSMO)]. Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. *Ann Gastroenterol*. 2016 Jan-Mar;29(1):3-17. PubMed PMID: 26752945; PubMed Central PMCID: PMC4700843.
190. Kountourakis P, Souglakos J, Gouvas N, Androulakis N, Athanasiadis A, Boukovinas I, Christodoulou C, Chrysou E, Dervenis C, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Makatsoris T, Papakostas P, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Xynos E, Ziras N, Papamichael D. Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. *Ann Gastroenterol*. 2016 Jan-Mar;29(1):18-23. PubMed PMID: 26751386; PubMed Central PMCID: PMC4700841.
191. Karavasilis V, Papadimitriou C, Gogas H, Kouvatseas G, Pentheroudakis G, Koutras A, Christodoulou C, Bafaloukos D, Samantas E, Pisanidis N, Papakostas P, Aravantinos G, Karanikiotis C, Kosmidis P, Pectasides D, Dimopoulos MA, Fountzilas G. Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. *Clin Breast Cancer*. 2015 Dec 17. pii: S1526-8209(15)00296-7. doi: 10.1016/j.clbc.2015.12.001. [Epub

ahead of print] PubMed PMID: 26791750.

192. Makatsoris T, Tsamandas AC, Strimpakos A, Alexopoulou Z, Dionysopoulos D, Pervana S, Konstantara A, Papakostas P, Samantas E, Rallis G, Dimou A, Pentheroudakis G, Papaparaskeva K, Psyrii A, Kalogeras KT, Syrigos K, Scopa CD, Fountzilas G. HER Family Protein Expression in a Greek Population with Gastric Cancer. A Retrospective Hellenic Cooperative Oncology Group Study. *Anticancer Res.* 2016 Apr;36(4):1581-90. PubMed PMID: 27069134.
193. Xynos E, Tekkis P, Gouvas N, Vini L, Chrysou E, Tzardi M, Vassiliou V, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Triantopoulou C, Xynogalos S, Karachaliou N, Ziras N, Zoras O, Souglakos J; [the Executive Team on behalf of the Hellenic Society of Medical Oncologists (HeSMO)]. Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). *Ann Gastroenterol.* 2016 Apr-Jun;29(2):103-26. doi: 10.20524/aog.2016.0003. PubMed PMID: 27064746; PubMed Central PMCID: PMC4805730.
194. Lakis S, Dimoudis S, Kotoula V, Alexopoulou Z, Kostopoulos I, Koletsa T, Bobos M, Timotheadou E, Papaspirou I, Efstratiou I, Aravantinos G, Karavasilis V, Zagouri F, Gogas H, Razis E, Pentheroudakis G, Christodoulou C, Pectasides D, Fountzilas G. Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. *Anticancer Res.* 2016 May;36(5):2365-78. PubMed PMID: 27127145.
195. Fountzilas G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poullos C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, Dimopoulos MA, Kotoula V. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. **Oncotarget.** 2016 May 31;7(22):32731-53. doi: 10.18632/oncotarget.9022.
196. Fotopoulos G, Rashad N, Pentheroudakis G, Aboukassam F, Khaled H, et al. (2014) Comparative Observational Study of Two Ethnic Population Groups of Patients with Hepatocellular Carcinoma. *J Clin Exp Oncol* 3:3. doi:10.4172/2324-9110.1000129
197. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Rieke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ,

Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol*. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5. PubMed PMID: 27380959.

198. Kotoula V, Karavasilis V, Zagouri F, Kouvatseas G, Giannoulatou E, Gogas H, Lakis S, Pentheroudakis G, Bobos M, Papadopoulou K, Tsolaki E, Pectasides D, Lazaridis G, Koutras A, Aravantinos G, Christodoulou C, Papakostas P, Markopoulos C, Zografos G, Papandreou C, Fountzilas G. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. *Breast Cancer Res Treat*. 2016 Jul;158(2):307-21. doi: 10.1007/s10549-016-3883-z. Epub 2016 Jul 1. PubMed PMID: 27369359.

199. Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. *Eur J Surg Oncol*. 2017 Jan;43(1):32-41. doi: 10.1016/j.ejso.2016.05.026. Epub 2016 Jun 1. Review. PubMed PMID: 27283892.

200. Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. *J Transl Med*. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z. PubMed PMID: 27184134; PubMed Central PMCID: PMC4869295.

201. Yannis Metaxas, Georgios Oikonomopoulos, George Pentheroudakis. Update on clinical research and state of the art management of patients with advanced sarcomas and GIST. *ESMO Open*. 2016 May 20;1(3):e000065. eCollection 2016. Review.

202. Economopoulou P, Pentheroudakis G. Cancer of unknown primary: time to put the pieces of the puzzle together? *Lancet Oncol*. 2016 Oct;17(10):1339-1340 doi: 10.1016/S1470-2045(16)30377-1. PubMed PMID: 27575025.

203. Nearchou A, Pentheroudakis G. The significance of tumor-associated immune response in molecular taxonomy, prognosis and therapy of colorectal cancer patients. *Ann Transl Med*. 2016 Jul;4(14):271. doi: 10.21037/atm.2016.05.54. Review. PubMed PMID: 27563658; PubMed Central PMCID: PMC4971377.

204. Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis

G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). *ESMO Open*. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. Review. PubMed PMID: 28255451; PubMed Central PMCID: PMC5174792.

205. Psyrris A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Economopoulou P, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. *J Transl Med*. 2017 Feb 13;15(1):30. doi: 10.1186/s12967-017-1134-7. PubMed PMID: 28193231.

206. Kotoula V, Fostira F, Papadopoulou K, Apostolou P, Tsolaki E, Lazaridis G, Manoussou K, Zagouri F, Pectasides D, Vlachos I, Tikas I, Lakis S, Konstantopoulou I, Pentheroudakis G, Gogas H, Papakostas P, Christodoulou C, Bafaloukos D, Razis E, Karavasilis V, Bamias C, Yannoukakos D, Fountzilas G. The fate of BRCA1-related germline mutations in triple-negative breast tumors. *Am J Cancer Res*. 2017 Jan 1;7(1):98-114. PubMed PMID: 28123851; PubMed Central PMCID: PMC5250684.

207. Boussios S, Seraj E, Zarkavelis G, Petrakis D, Kollas A, Kafantari A, Assi A, Tatsi K, Pavlidis N, Pentheroudakis G. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. *Crit Rev Oncol Hematol*. 2016 Dec;108:164-174. doi: 10.1016/j.critrevonc.2016.11.006. Review. PubMed PMID: 27931835.

208. Pectasides D, Kotoula V, Papaxoinis G, Alexopoulou Z, Dervenis C, Samantas E, Papaparaskeva K, Charalambous E, Gkakou C, Agalianos C, Kalogeras KT, Pentheroudakis G, Fountzilas G. Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. *Anticancer Res*. 2016 Dec;36(12):6347-6356. PubMed PMID: 27919956.

209. Fountzilas E, Kotoula V, Zagouri F, Giannoulatou E, Kouvatseas G, Pentheroudakis G, Koletsa T, Bobos M, Papadopoulou K, Samantas E, Demiri E, Miliaras S, Christodoulou C, Chrisafi S, Razis E, Fostira F, Pectasides D, Zografos G, Fountzilas G. Disease evolution and heterogeneity in bilateral breast cancer. *Am J Cancer Res*. 2016 Nov 1;6(11):2611-2630. PubMed PMID: 27904775; PubMed Central PMCID: PMC5126277.

210. Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G. Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. *Anticancer Res*. 2016 Oct;36(10):5031-5042. Review. PubMed PMID: 27798862.



211. Dervenis C, Xynos E, Sotiropoulos G, Gouvas N, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Chrysou E, Emmanouilidis C, Georgiou P, Karachaliou N, Katopodi O, Kountourakis P, Kyriazanos I, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Tekkis P, Triantopoulou C, Tzardi M, Vassiliou V, Vini L, Xynogalos S, Ziras N, Souglakos J. Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). *Ann Gastroenterol*. 2016 Oct-Dec;29(4):390-416. PubMed PMID: 27708505; PubMed Central PMCID: PMC5049546.
212. Stavridi F, Kalogeras KT, Pliarchopoulou K, Wirtz RM, Alexopoulou Z, Zagouri F, Veltrup E, Timotheadou E, Gogas H, Koutras A, Lazaridis G, Christodoulou C, Pentheroudakis G, Laskarakis A, Arapantoni-Dadioti P, Batistatou A, Sotiropoulou M, Aravantinos G, Papakostas P, Kosmidis P, Pectasides D, Fountzilias G. Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. *PLoS One*. 2016 Oct 3;11(10):e0164013. doi: 10.1371/journal.pone.0164013. PubMed PMID: 27695115; PubMed Central PMCID: PMC5047528.
213. Kotoula V, Lakis S, Vlachos IS, Giannoulatou E, Zagouri F, Alexopoulou Z, Gogas H, Pectasides D, Aravantinos G, Efstratiou I, Pentheroudakis G, Papadopoulou K, Chatzopoulos K, Papakostas P, Sotiropoulou M, Nicolaou I, Razis E, Psyrri A, Kosmidis P, Papadimitriou C, Fountzilias G. Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. *PLoS One*. 2016 Sep 29;11(9):e0163138. doi: 10.1371/journal.pone.0163138. PubMed PMID: 27685159; PubMed Central PMCID: PMC5042538.
214. Boussios S, Zerdes I, Batsi O, Papakostas VP, Seraj E, Pentheroudakis G, Glantzounis GK. Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence. *Int J Surg Case Rep*. 2016;27:198-201. doi: 10.1016/j.ijscr.2016.08.039. PubMed PMID: 27661665; PubMed Central PMCID: PMC5035354.
215. Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulias K, Karavasilis V, Pentheroudakis G, Balassi E, Zagouri F, Kaklamanos IG, Pectasides D, Razis E, Aravantinos G, Papakostas P, Bafaloukos D, Rallis G, Gogas H, Fountzilias G. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. *Cancer Genomics Proteomics*. 2017 May-Jun;14(3):181-195. PubMed PMID: 28446533.
216. Cohen SA, Yu M, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilias G, Grady WM. The CpG island methylator phenotype is concordant between primary colorectal

- carcinoma and matched distant metastases. *Clin Epigenetics*. 2017 May 2;9:46. doi: 10.1186/s13148-017-0347-1. eCollection 2017. PubMed PMID: 28469732; PubMed Central PMCID: PMC5414304.
217. Cherny NI, Dafni U, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE. Reply to the letter to the editor "Addressing the Quality of the ESMO-MCBS" by Del Paggio. *Ann Oncol*. 2017 Apr 18. doi: 10.1093/annonc/mdx200. [Epub ahead of print] PubMed PMID: 28430861.
218. Timotheadou E, Kalogeras KT, Koliou GA, Wirtz RM, Zagouri F, Koutras A, Veltrup E, Christodoulou C, Pentheroudakis G, Tsiftoglou A, Papakostas P, Aravantinos G, Venizelos V, Pectasides D, Kosmidis P, Karanikiotis C, Markopoulos C, Gogas H, Fountzilas G. Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. *Transl Oncol*. 2017 Jun 27;10(4):589-598. doi: 10.1016/j.tranon.2017.05.006. [Epub ahead of print] PubMed PMID: 28666187.
219. Strati TM, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Lazaridis G, Lakis S, Pentheroudakis G, Pectasides D, Pazarli E, Christodoulou C, Razis E, Pavlakis K, Magkou C, Chrisafi S, Aravantinos G, Bafaloukos D, Papakostas P, Gogas H, Kalogeras KT, Fountzilas G. Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. *Anticancer Res*. 2017 May;37(5):2323-2334. PubMed PMID: 28476798.
220. Kyriakopoulos C, Zarkavelis G, Andrianopoulou A, Papoudou-Bai A, Stefanou D, Boussios S, Pentheroudakis G. Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review. *Case Rep Oncol Med*. 2017;2017:8654326. doi: 10.1155/2017/8654326. Epub 2017 Mar 2. PubMed PMID: 28352484; PubMed Central PMCID: PMC5352873.
221. Zagouri F, Kotoula V, Kouvatseas G, Sotiropoulou M, Koletsa T, Gavressea T, Valavanis C, Trihia H, Bobos M, Lazaridis G, Koutras A, Pentheroudakis G, Skarlos P, Bafaloukos D, Arnogiannaki N, Chrisafi S, Christodoulou C, Papakostas P, Aravantinos G, Kosmidis P, Karanikiotis C, Zografos G, Papadimitriou C, Fountzilas G. Protein expression patterns of cell cycle regulators in operable breast cancer. *PLoS One*. 2017 Aug 10;12(8):e0180489. doi: 10.1371/journal.pone.0180489. eCollection 2017. PubMed PMID: 28797035; PubMed Central PMCID: PMC5552326.
222. Tabernero J, Vyas M, Giuliani R, Arnold D, Cardoso F, Casali PG, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, Rauh S, Zielinski CC, Stahel RA, Voest E, Douillard JY, McGregor K, Ciardiello F. Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. *ESMO Open*. 2017 Jan 16;1(6):e000142. doi: 10.1136/esmoopen-2016-000142. eCollection 2016. Review. PubMed PMID: 28848668; PubMed Central PMCID: PMC5419210.

223. Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Koutras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsa T, Razis E, Kosmidis P, Aravantinos G, Papadimitriou C, Pectasides D, Fountzilias G. Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. *Clin Breast Cancer*. 2017 Jul 13. pii: S1526-8209(17)30138-6. doi: 10.1016/j.clbc.2017.07.004. [Epub ahead of print] PubMed PMID: 28870680.
224. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. ESMO-Magnitude of Clinical Benefit Scale version 1.1. *Ann Oncol*. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310. PubMed PMID: 28945867.
225. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Toxicity Adjustment in the ESMO-MCBS: A diligent process of data interpretation with peer review that is far from "Gestalt". *Ann Oncol*. 2017 Oct 12. doi: 10.1093/annonc/mdx649. [Epub ahead of print] PubMed PMID: 29045537.
226. Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI. Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. *ESMO Open*. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017. PubMed PMID: 29067214; PubMed Central PMCID: PMC5640101.
227. Kastrisiou M, Kostadima FL, Kefas A, Zarkavelis G, Kapodistrias N, Ntouvelis E, Petrakis D, Papadaki A, Vassou A, Pentheroudakis G. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. *ESMO Open*. 2017 Oct 5;2(4):e000217. doi: 10.1136/esmoopen-2017-000217. eCollection 2017. PubMed PMID: 29067215; PubMed Central PMCID: PMC5640091.
228. Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. *Ann Gastroenterol*. 2017;30(6):613-621. doi: 10.20524/aog.2017.0191. Epub 2017 Sep 22. Review. PubMed PMID: 29118555; PubMed Central PMCID: PMC5670280.
229. Tsoulos N, Papadopoulou E, Metaxa-Mariatou V, Tsaousis G, Efstathiadou C, Tounta G, Scapeti A, Bourkoula E, Zarogoulidis P, Pentheroudakis G, Kakolyris S, Boukovinas I, Papakotoulas P, Athanasiadis E, Floros T, Koumariou A, Barbounis V, Dinischiotu A, Nasioulas G. Tumor molecular profiling of NSCLC patients using

next generation sequencing. *Oncol Rep.* 2017 Dec;38(6):3419-3429. doi: 10.3892/or.2017.6051. Epub 2017 Oct 23. PubMed PMID: 29130105.

230. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. *Ann Oncol.* 2017 Nov 16. doi: 10.1093/annonc/mdx738. [Epub ahead of print] PubMed PMID: 29155929.

231. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Reply to: Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks or Modern Cancer Therapies. *Ann Oncol.* 2017 Nov 17. doi: 10.1093/annonc/mdx747. [Epub ahead of print] PubMed PMID: 29161364.

232. Tzamakou E, Petrou A, Tefa L, Sifaka V, Laou E, Tzimas P, Pentheroudakis G, Papadopoulos G. Detection of neuropathic pain in end-stage cancer patients: diagnostic accuracy of two questionnaires. *Pain Pract.* 2017 Dec 8. doi: 10.1111/papr.12671. [Epub ahead of print] PubMed PMID: 29222840.

233. Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G, Felekouras E. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. *Eur J Surg Oncol.* 2017 Dec 12. pii: S0748-7983(17)31012-0. doi: 10.1016/j.ejso.2017.11.022. [Epub ahead of print] Review. PubMed PMID: 29258719.

234. Boussios S, Zerdes I, Vassou A, Baretta E, Seraj E, Papoudou-Bai A, Pavlidis N, Batistatou A, Pentheroudakis G. Extranodal diffuse large B-cell lymphomas: A retrospective case series and review of the literature. *Hematol Rep.* 2018 Apr 3;10(1):7070. doi: 10.4081/hr.2018.7070. eCollection 2018 Mar 2. DOI: 10.4081/hr.2018.7070  
PMCID: PMC5907641  
PMID: 29721249

235. Cherny NI, Dafni U, Piccart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE. Reply to "ESMO-MCBS v1.1: Statistical and Patient Relevant Shortcomings" by R. Emprechtinger et al. *Ann Oncol.* 2018 Apr 5. doi: 10.1093/annonc/mdy108. [Epub ahead of print] DOI: 10.1093/annonc/mdy108 PMID: 29659680

236. Mavroeidis L, Metaxa-Mariatou V, Papoudou-Bai A, Lampraki,

Kostadima L, Tsinokou I, Zarkavelis G, Papadaki A, Petrakis D, Gxoura S, Kampletsas E, Nasioulas G, Batistatou A, Pentheroudakis G.

Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFR genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece. *ESMO Open*. 2018 Apr 6;3(3):e000335. doi: 10.1136/esmoopen-2018-000335. eCollection 2018.

DOI: 10.1136/esmoopen-2018-000335

PMCID: PMC5890860

PMID: 29636989

237. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Taberero J, Zielinski C, Piccart MJ, de Vries EGE.

RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.

*J Natl Cancer Inst*. 2018 Mar 12. doi: 10.1093/jnci/djy029. [Epub ahead of print]

DOI: 10.1093/jnci/djy029 PMID: 29546378

238. Postoperative chemotherapy with single agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomized trials.

Davide Mauri<sup>1,2</sup>, George Zarkavelis<sup>1,2</sup>, Panagiotis Filis<sup>1,2</sup>, Lampriani Tsali<sup>3</sup>, Georgia Zafeiri<sup>1,2</sup>, Alexandra Papadaki<sup>1,2</sup>, Amalia Vassou<sup>4</sup>, Christos Georgopoulos<sup>1,2</sup>, George Pentheroudakis<sup>1,2</sup>

*ESMO Open*

DOI: [10.1136/esmoopen-2018-000343](https://doi.org/10.1136/esmoopen-2018-000343)

239. Clonal evolution of colorectal cancer in a patient with serially resected metastases and liquid biopsies: A case report and discussion of the literature.

Myrto Kastrisiou<sup>1</sup>, George Zarkavelis<sup>1</sup>, Eleftherios Kampletsas<sup>1</sup>, Eleni Panopoulou<sup>2</sup>, Anna Goussia<sup>2</sup>, George Nasioulas<sup>3</sup>, Eirini Papadopoulou<sup>3</sup>, Christina Tsaousi<sup>4</sup>, George Pentheroudakis<sup>1</sup>

*ESMO Open*

DOI: [10.1136/esmoopen-2018-000329](https://doi.org/10.1136/esmoopen-2018-000329)

240. The role of chemotherapy in resectable liver metastases from colorectal cancer: food for thought from pooled evidence.

Mauri D, Filis P, Tsali L, Zarkavelis G, Pentheroudakis G.

*ESMO Open*

DOI: 10.1136/2018-000367

241. Apostolou P, Fostira F, Mollaki V, Delimitsou A, Vlassi M, Pentheroudakis G, Faliakou E, Kollia P, Fountzilias G, Yannoukakos D, Konstantopoulou I.

Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients.

*J Hum Genet*. 2018 May 22. doi: 10.1038/s10038-018-0466-3.

[Epub ahead of print] PubMed PMID: 29785007.

242. Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M,

Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. *J Clin Oncol*. 2019 Feb 1;37(4):336-349. doi: 10.1200/JCO.18.00729. Epub 2018 Dec 17. PubMed PMID: 30707056.

243: Ntellas P, Dadouli K, Perivoliotis K, Sogka E, Pentheroudakis G, Ioannou M, Hadjichristodoulou C, Tepetes K, Mauri D. Microvessel Density and Impact of Angiogenesis on Survival of Resected Pancreatic Cancer Patients: A Systematic Review and Meta-analysis. *Pancreas*. 2019 Feb;48(2):233-241. doi: 10.1097/MPA.0000000000001237. PubMed PMID: 30629030.

244: Zarkavelis G, Pentheroudakis G. TAILORing targeted therapies to the right patient at the right time: how close are we? *Ann Transl Med*. 2018 Nov;6(Suppl 1):S87. doi: 10.21037/atm.2018.10.75. PubMed PMID: 30613662; PubMed Central PMCID: PMC6291566.

245: Gourzoulidis G, Maniadakis N, Petrakis D, Souglakos J, Pentheroudakis G, Kourlaba G. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece. *J Comp Eff Res*. 2019 Feb;8(3):133-142. doi: 10.2217/cer-2018-0076. Epub 2018 Dec 14. PubMed PMID: 30547679.

246: Kotoula V, Tsakiri K, Koliou GA, Lazaridis G, Papadopoulou K, Giannoulatou E, Tikas I, Christodoulou C, Chatzopoulos K, Bobos M, Pentheroudakis G, Tsolaki E, Batistatou A, Kotsakis A, Koutras A, Linardou H, Razis E, Res E, Pectasides D, Fountzilas G. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome. *Clin Breast Cancer*. 2018 Nov 5. pii: S1526-8209(18)30424-5. doi: 10.1016/j.clbc.2018.10.014. [Epub ahead of print] PubMed PMID: 30545790.

247: Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, Kotoula V, Batistatou A, Bobos M, Tsolaki E, Papadopoulou K, Pentheroudakis G, Papakostas P, Pervana S, Petraki K, Chrisafi S, Razis E, Psyri A, Bafaloukos D, Kalogeras KT, Kalofonos HP, Fountzilas G. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study. *PLoS One*. 2018 Dec 6;13(12):e0207707. doi: 10.1371/journal.pone.0207707. eCollection 2018. PubMed PMID: 30521571; PubMed Central PMCID: PMC6283464.

248: Karavasilis V, Samantas E, Koliou GA, Kalogera-Fountzila A, Pentheroudakis G, Varthalitis I, Linardou H, Rallis G, Skondra M, Papadopoulos G, Papatsibas G, Sgouros J, Goudopoulou A, Kalogeras KT, Dervenis C, Pectasides D, Fountzilas G. Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology

Group Phase I/II Study. *Target Oncol.* 2018 Dec;13(6):715-724. doi: 10.1007/s11523-018-0605-y. PubMed PMID: 30488350.

249: Fountzilas E, Kotoula V, Tikas I, Manousou K, Papadopoulou K, Poullos C, Karavasilis V, Efstratiou I, Pectasides D, Papaparaskeva K, Varthalitis I, Christodoulou C, Papatsibas G, Chrisafi S, Glantzounis GK, Psyri A, Aravantinos G, Koliou GA, Koukoulis GK, Pentheroudakis GE, Fountzilas G. Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. *Oncotarget.* 2018 Nov 2;9(86):35623-35638. doi: 10.18632/oncotarget.26256. eCollection 2018 Nov 2. PubMed PMID: 30479693; PubMed Central PMCID: PMC6235022.

250: Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol.* 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502. PubMed PMID: 30475956.

251: Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol.* 2019 Jan 1;30(1):34-43. doi: 10.1093/annonc/mdy498. PubMed PMID: 30475943.

252: Christodoulou C, Oikonomopoulos G, Koliou GA, Kostopoulos I, Kotoula V, Bobos M, Pentheroudakis G, Lazaridis G, Skondra M, Chrisafi S, Koutras A, Bafaloukos D, Razis E, Papadopoulou K, Papakostas P, Kalofonos HP, Pectasides D, Skarlos P, Kalogeras KT, Fountzilas G. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab. *Cancer Genomics Proteomics.* 2018 Nov-Dec;15(6):461-471. doi: 10.21873/cgp.20105. PubMed PMID: 30343280; PubMed Central PMCID: PMC6299784.

253: Tsiatas M, Kalogeras KT, Manousou K, Wirtz RM, Gogas H, Veltrup E, Zagouri F, Lazaridis G, Koutras A, Christodoulou C, Pentheroudakis G, Petraki C, Bafaloukos D, Pectasides D, Kosmidis P, Samantas E, Karanikiotis C, Papakostas P, Dimopoulos MA, Fountzilas G. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. *Cancer Med.* 2018 Oct;7(10):5066-5082. doi: 10.1002/cam4.1730. Epub 2018 Sep 21. PubMed PMID: 30240146; PubMed Central PMCID:

PMC6198219.

254: Mauri D, Zafeiri G, Tsali L, Chalkidou A, Zarkavelis G, Papadaki A, Filis P, Pentheroudakis G. Identification of catheter misplacement in early port CVC dysfunction. *Contemp Oncol (Pozn)*. 2018;22(2):129-134. doi: 10.5114/wo.2018.77044. Epub 2018 Jun 30. PubMed PMID: 30150892; PubMed Central PMCID: PMC6103231.

255: Goussia A, Simou N, Zagouri F, Manousou K, Lazaridis G, Gogas H, Koutras A, Sotiropoulou M, Pentheroudakis G, Bafaloukos D, Markopoulos C, Patsea H, Christodoulou C, Papakostas P, Zaramboukas T, Samantas E, Kosmidis P, Venizelos V, Karanikiotis C, Papatsibas G, Xepapadakis G, Kalogeras KT, Bamia C, Dimopoulos MA, Malamou-Mitsi V, Fountzilias G, Batistatou A. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. *PLoS One*. 2018 Jul 31;13(7):e0200302. doi: 10.1371/journal.pone.0200302. eCollection 2018. PubMed PMID: 30063723; PubMed Central PMCID: PMC6067711.

256: Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. *Br J Cancer*. 2018 Aug;119(3):303-312. doi: 10.1038/s41416-018-0165-z. Epub 2018 Jul 17. PubMed PMID: 30013091.

257: Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poullos C, Voutsina A, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilias G. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. 2018 Dec;17(4):e631-e637. doi: 10.1016/j.clcc.2018.06.003. Epub 2018 Jun 15. PubMed PMID: 29980490.



## B. CHAPTERS WRITTEN IN MEDICAL BOOKS

1. «Adolescent and Young Adult Oncology», N. Pavlidis et al., 2004, Ed. Paschalidis, Athens, ISBN 9603992062.
  - Testicular cancer.
  - Extragonadal germ cell tumors.
  - Ovarian germ cell cancer.
  - Outer consequences of anti-neoplastic therapy.
  
2. «Pregnancy and cancer», N. Pavlidis et al., 2006, Ed. Paschalidis, Athens, ISBN 960-399-419-7.
  - Gastrointestinal cancer and pregnancy.
  - Lymphomas and pregnancy.
  
3. «Modern Mastology», 2nd Ed., L.Ioannidou-Mouzaka, 2006, eds, Athens, ISBN 978-960-399-605-7.
  - Cytoprotectives, present and future.
  - Breast cancer and pregnancy.
  
4. «Recent Reviews in Cancer Research-Cancer and Pregnancy», A. Surbone, F. Peccatori, N. Pavlidis, Eds Springer Verlag Vol 178, 2008 XII, ISBN 978-3-540-71272-5.
  - Gastrointestinal, urologic and lung malignancies during pregnancy.
  - Metastatic involvement of the placenta and fetus.
  
5. "Basic principles of cancer treatment" G. Fountzilas-V. Barmponis, 2nd Edition, Ed. University Studio Press, Thessaloniki 2006, ISBN 960-12-1497-6.
  - Pregnancy and cancer.
  
6. "Cancer of Unknown Primary", Wick MR, Demos Publishing Company, 1st Edition, New York, 2007.
  - Tumor markers in CUP.
  
7. «Cancer Handbook», Oxford Deskbook Reference Series, Oxford, 2008.
  - Cancer and Pregnancy.
  - Cancer of unknown primary.
  
8. Treatment Strategies 2010, Oxford, 2010.
  - Recent advances in Cancer of Unknown Primary
  - Recent advances in Gastrointestinal Neuroendocrine tumors
  
9. Gynecologic Oncology, Athens, Paschalidis 2012, ISBN 960-8122-73-0.
  - Heritable Gynecologic Cancer.
  - Gynecologic cancers during pregnancy.

10. Oxford Textbook of Oncology 3e, Oxford University Press 2015.  
Edited by David J. Kerr, Daniel G. Haller, Cornelis J. H. van de Velde, and Michael Baumann  
- Cancer of Unknown Primary site  
Publisher: Oxford University Press Print Publication Date: Jan 2016 Print ISBN-13: 9780199656103 Published online: Jan 2016 DOI: 10.1093/med/9780199656103.001.0001
11. Acute Leukemia. The scientist's perspective and challenge. Edited by Mariastefania Antica, INTECH, ISBN 978-953-307-553-2  
- Solid tumors during pregnancy  
- Leukemias lymphomas during pregnancy
12. UICC Manual of Clinical Oncology, 2013  
- «Cancer of Unknown Primary».
13. European Society of Medical Oncology (ESMO) «Sarcoma, Skin Cancers and CUP: Essentials for Clinicians»  
- «Cancer of Unknown Primary», in press.